


## Mid-Term Real World Outcomes of the Hydrus® Microstent in Open Angle Glaucoma


Figure 1. Average medicated IOP development. Course of the average medicated IOP and the average number of eye drops.



M, month.


## Mid-Term Real World Outcomes of the Hydrus® Microstent in Open Angle Glaucoma

**Figure 2.** Kaplan Meier curves on IOP. Kaplan-Meter survival analysis (survival was defined by a reduction in IOP  $\geq 20\%$  compared to the baseline values in reference to different target IOP level).



# Ab Interno Minimally Invasive Glaucoma Surgery Combined with Cataract Surgery and Cataract Surgery Alone: IRIS® Registry Study

**Figure 2.** Mean IOP value for patients with A) baseline >18 mmHg and B) baseline <18 mmHg, and mean number of medications used for patients with C) baseline >18 mmHg and D) baseline <18 mmHg.



# Effectiveness of Angle Based Minimally Invasive Glaucoma Surgery After Laser Trabeculoplasty: An Analysis of the IRIS® Registry

